Whether these mutations have a prognostic or predictive value remains elusive. Furthermore, the clinical relevance of the extended RAS (KRAS+NRAS) mutational status is unclear in PC. We ...

These inhibitors use a different mechanism of action than most other KRAS inhibitors (including that in the previous study) ...

Erasca continues developing novel RAS-pathway cancer drugs, backed by funding through 2027 and promising early results. Find ...

HonorHealth Research Institute's new downtown Phoenix laboratory has produced its first study, centered on a promising new ...

as well as the potential expanded therapeutic index of ERAS-4001 through selective targeting of key KRAS mutations. We are excited to achieve our goal of advancing development of both RAS ...

The real-time PCR-based companion diagnostic test identifies patients eligible for treatment with Amgen's Vectibix (panitumumab).

as well as the potential expanded therapeutic index of ERAS-4001 through selective targeting of key KRAS mutations. We are excited to achieve our goal of advancing development of both RAS ...

Sustained reactivation of mutant p53 drives durable anti-tumor activity across models, including KRAS co-mutant tumorsFMC-220 selectively stabilizes p53 Y220C at lower doses, overcoming key ...

Preclinical data demonstrates synergy of QTX3544 with EGFR inhibitors, broadly enhancing anti-tumor activity - - Data supports ongoing Phase 1 clinical trial for QTX3544 as monotherapy and in ...

First-in-class examples of direct SHOC2 binders and modulators of SMP complex assembly identified with potential to block oncogenic RAS/MAPK pathway signaling SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE ...